Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Mehmet Erdem Cakmak; Saltuk Bugra Kaya; Ozge Can Bostan; Gülseren Tuncay; Ebru Damadoglu; Gül Karakaya; Ali Fuat Kalyoncu

doi:10.21911/AAI.584

Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Mehmet Erdem Cakmak
, Saltuk Bugra Kaya
, Ozge Can Bostan
, Gülseren Tuncay
, Ebru Damadoglu
, Gül Karakaya
, Ali Fuat Kalyoncu

Division of Pulmonology

Hacettepe University

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.

Original language	English
Pages (from-to)	27-29
Number of pages	3
Journal	Asthma Allergy Immunology
Volume	18
DOIs	https://doi.org/10.21911/AAI.584
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anti-ige
Asthma
Covid-19
Omalizumab
Severe allergic asthma

Access to Document

10.21911/AAI.584

Cite this

@article{72b25522c129419eb4cd4085e986ada5,

title = "Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report",

abstract = "Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.",

keywords = "Anti-ige, Asthma, Covid-19, Omalizumab, Severe allergic asthma",

author = "Cakmak, \{Mehmet Erdem\} and Kaya, \{Saltuk Bugra\} and Bostan, \{Ozge Can\} and G{\"u}lseren Tuncay and Ebru Damadoglu and G{\"u}l Karakaya and Kalyoncu, \{Ali Fuat\}",

year = "2020",

doi = "10.21911/AAI.584",

language = "English",

volume = "18",

pages = "27--29",

journal = "Asthma Allergy Immunology",

issn = "1308-9234",

publisher = "Turkish National Society of Allergy and Clinical Immunology",

}

TY - JOUR

T1 - Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment

T2 - A Case Report

AU - Cakmak, Mehmet Erdem

AU - Kaya, Saltuk Bugra

AU - Bostan, Ozge Can

AU - Tuncay, Gülseren

AU - Damadoglu, Ebru

AU - Karakaya, Gül

AU - Kalyoncu, Ali Fuat

PY - 2020

Y1 - 2020

N2 - Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.

AB - Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.

KW - Anti-ige

KW - Asthma

KW - Covid-19

KW - Omalizumab

KW - Severe allergic asthma

UR - https://www.scopus.com/pages/publications/85118657184

U2 - 10.21911/AAI.584

DO - 10.21911/AAI.584

M3 - Article

AN - SCOPUS:85118657184

SN - 1308-9234

VL - 18

SP - 27

EP - 29

JO - Asthma Allergy Immunology

JF - Asthma Allergy Immunology

ER -

Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this